ICJIM

The Intercontinental Journal of Internal Medicine aims to publish issues related to all fields of internal medicine of the highest scientific and clinical value at an international level and accepts articles on these topics.

EndNote Style
Index
Original Article
Epstein-Barr virus RNA percentage and its impact on prognosis in patients with diffuse large B-cell lymphoma
Aims: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphomas. This study aimed to investigate the impact of Epstein-Barr virus RNA (EBER) positivity on the prognosis of patients diagnosed with DLBCL.
Methods: This retrospective study was conducted on 105 patients diagnosed with DLBCL at Sivas Cumhuriyet University Hospital between June 1, 2009, and May 31, 2022.
Results: Of the 105 patients, 55.2% were male, and the mean age was 56.89 years. EBER positivity was detected in 4.8% of the patients. While 71% of EBER-negative patients achieved a complete response, overall survival and progression-free survival were shorter in EBER-positive patients. However, no significant relationship was observed between EBER positivity and prognostic indices (IPI, R-IPI, NCCN-IPI).
Conclusion: The findings of this study indicate that EBER positivity could act as a prognostic indicator, given its association with unfavorable survival rates and diminished response to treatment in individuals with DLBCL.


1. Sethi A, Tandon A, Mishra H, Singh I. Diffuse large B-cell lymphoma: An immunohistochemical approach to diagnosis. J Oral Maxillofac Pathol. 2019;23(2):284-288. doi:10.4103/jomfp.JOMFP_294_18
2. Wang SS. Epidemiology and etiology of diffuse large B-cell lymphoma. Semin Hematol. 2023;60(5):255-266. doi:10.1053/j.seminhematol.2023.11.004
3. Healy JA, Dave SS. The role of EBV in the pathogenesis of diffuse large B cell lymphoma. Curr Top Microbiol Immunol. 2015;390(Pt 1):315-337. doi:10.1007/978-3-319-22822-8_13
4. Bahar AY, Kazanci U. EBV incidence in diffuse large B-cell lymphoma: a single center descriptive study. Selcuk Med J. 2020;36(2):129-137. doi:10. 30733/std.2020.01339
5. Lu CH, Lee KF, Chen CC, et al. Clinical characteristics and treatment outcome in a Taiwanese population of patients with Epstein-Barr virus-positive diffuse large B-cell lymphoma. Jpn J Clin Oncol. 2014;44(12): 1164-1171. doi:10.1093/jjco/hyu155
6. Buğra A, Yıldız FR, Özekinci S, Ayaz G, Erdem ZB, Çakır Ç. Diffüz büyük B hücreli lenfoma olgularında kromojen in Situ hibridizasyon yöntemi ile Epstein Barr virüs varlığının araştırılması. J Curr Pathol. 2019;2:84-92. doi:10.5146/jcpath.2019.50
7. Ziarkiewicz M, Wolosz D, Dzieciatkowski T, et al. Epstein-Barr virus-positive diffuse large B cell lymphoma in the experience of a tertiary medical center in Poland. Arch Immunol Ther Exp (Warsz). 2016;64(2): 159-169. doi:10.1007/s00005-015-0341-2
8. Ok CY, Li L, Xu-Monette ZY, et al. Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries Clin Cancer Res. 2014;20(9):2338-2349. doi:10.1158/ 1078-0432.CCR-13-3157
9. Liang JH, Lu TX, Tian T, et al. Epstein-Barr virus (EBV) DNA in whole blood as a superior prognostic and monitoring factor than EBV-encoded small RNA in situ hybridization in diffuse large B-cell lymphoma. Clin Microbiol Infect. 2015;21(6):596-602. doi:10.1016/j.cmi.2015.02.017
10. Okamoto A, Yanada M, Inaguma Y, et al. The prognostic significance of EBV DNA load and EBER status in diagnostic specimens from diffuse large B-cell lymphoma patients. Hematol Oncol. 2017;35(1):87-93. doi: 10.1002/hon.2245
11. Hong JY, Yoon DH, Suh C, et al. EBV-positive diffuse large B-cell lymphoma in young adults: is this a distinct disease entity? Ann Oncol. 2015;26(3):548-555. doi:10.1093/annonc/mdu556
12. Tracy SI, Habermann TM, Feldman AL, et al. Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression. Haematologica. 2018;103(2):297-303. doi:10.3324/haematol.2017.176511
13. Chang ST, Lu YH, Lu CL, et al. Epstein-Barr virus is rarely associated with diffuse large B cell lymphoma in Taiwan and carries a trend for a shorter median survival time. J Clin Pathol. 2014;67(4):326-332. doi:10. 1136/jclinpath-2013-201905
14. Gao X, Li J, Wang Y, Liu S, Yue B. Clinical characteristics and prognostic significance of EBER positivity in diffuse large B-cell lymphoma: a meta-analysis. PLoS One. 2018;13(6):e0199398. doi:10.1371/journal.pone. 0199398
15. Lu TX, Liang JH, Miao Y, et al. Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age. Sci Rep. 2015;5:12168. doi:10.1038/srep12168
16. Hong JY, Ryu KJ, Park C, et al. Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Oncotarget. 2017;8(8):13782-13791. doi:10.18632/oncotarget.14636
17. Ok CY, Papathomas TG, Medeiros LJ, Young KH. EBV-positive diffuse large B-cell lymphoma of the elderly. Blood. 2013;122(3):328-340. doi:10. 1182/blood-2013-03-489708
18. Sato A, Nakamura N, Kojima M, et al. Clinical outcome of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly in the rituximab era. Cancer Sci. 2014;105(9):1170-1175. doi:10.1111/cas.12467
19. Park S, Lee J, Ko YH, et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood. 2007;110(3): 972-978. doi:10.1182/blood-2007-01-067769
20. Jarrett RF, Stark GL, White J, et al. Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: a population-based study. Blood. 2005;106(7):2444-2451. doi:10.1182/blood-2004-09-3759
Volume 3, Issue 1, 2025
Page : 15-18
_Footer